VGXI Begins Expansion at Woodlands, Texas, Production Center
02/23/2018
According to company officials, once completed the project will increase the company’s footprint by 17% and its cGMP manufacturing space by over 70%.
The upcoming development will add two new flexible-use GMP production areas to serve clients with both large and small scale needs, and a range of products from DNA vaccines to plasmid raw material for GMP viral vector production.
“With three key approvals in 2017 for CAR-T and AAV therapies, the gene therapy industry is rapidly maturing,” said VGXI’s President & CEO, Young Park. “We are excited to support the needs of our growing client base with increased flexibility and capacity across all service levels from Pre-Clinical to Highly Documented (HD) and cGMP grade plasmid production.”
VGXI, a wholly-owned subsidiary CMO of South Korea-based GeneOne Life Science, Inc., was founded in 1997 and has been operating as a GMP plasmid contract manufacturing organization since 2004. Over the 15 year period, the company said it has continued to grow in response to an increasing demand for high quality DNA, with its most recent expansion completed in 2016.
Project Announcements
Campbell Soup Company Expands Richmond, Utah, Baking Operations
03/17/2024
Quantum Fuel Systems Plans Wixom, Michigan, Manufacturing Operations
03/17/2024
The Paslin Company Expands Pontiac-Shelby-Warren, Michigan, Operations
03/17/2024
Schneider Electric Plans-Expands Mt Juliet-Smyrna, Tennessee, Production Operations
03/15/2024
FreezPak Logistics Plans Suffolk, Virginia, Cold Storage Operations
03/15/2024
FrameTec Plans Casa Grande, Arizona, Production Operations
03/15/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The Logistics Analysis That Drives Industrial Site Selection
Q4 2023
-
2023 Top States Commentary: Top-Ranked States Have What It Takes to Win Mega Projects
Q3 2023
-
Technology’s Influence on Workforce Development
Workforce Q4 2023
-
AI 101 for Site Selection
Q4 2023
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023